<DOC>
	<DOCNO>NCT02788526</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) sixth common malignancy worldwide second leading cause cancer-related death . Surgical resection still main radical approach HCC , recurrence rate hepatectomy high , hamper improvement prognosis HCC patient . The conventional risk factor recurrence include : huge tumor , multiple lesion , vessel invasion tumor rupture . Recently , microvessels invasion ( MVI ) recognize novel risk factor recurrence hepatectomy . The investigator ' previous study show recurrence rate 50 % patient &gt; 5cm solitary tumor MVI . The MVI confirm independent risk factor overall disease-free survival HCC patient multiple variable analysis . It important reduce recurrence prolong survival patient hepatectomy effective adjuvant therapy . TACE utilized adjuvant therapy hepatectomy , significance still unknown . Then , investigator design current prospective randomize clinical trial evaluate effect adjuvant TACE reduce recurrence HCC patient high risk ( &gt; 5cm solitary tumor MVI ) resection , compare vigilant follow-up .</brief_summary>
	<brief_title>Adjuvant TACE Reduce HCC Recurrence After Resection</brief_title>
	<detailed_description>The patient solitary tumor 5cm microvessels invasion radical hepatectomy randomize receive adjuvant TACEï¼ˆ1~2 cycle , 4~6 week ) follow-up . The main endpoint : overall survival ( OS ) , disease-free survival ( DFS ) , safety compare two group .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Age 18~75 year ; 2 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) score &lt; =2 ; 3 . Histologically confirm hepatocellular carcinoma microvessels invasion ; 4 . No previous treatment HCC ; 5 . More 5 cm solitary tumor surgery confirm 2 radiological examination ; 6 . R0 resection achieve ; 7 . No recurrence evidence radiological followup 3~7 week surgery ; 8 . Adequate hematologic parameter liver kidney function : ( 1 ) Neutrophils Absolute &gt; =1.5*10^9/L ; ( 2 ) Hemoglobin &gt; =90g/L ; ( 3 ) Platelet count &gt; =75*10^9/L ; ( 4 ) Serum albumin &gt; =35g/L ; ( 5 ) Serum total bilirubin &lt; =1.5* upper limit normal ( ULN ) ; ( 6 ) Serum Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &lt; 2.5*ULN ; ( 7 ) Serum creatinine &lt; =1.5*ULN ; ( 8 ) International normalize ratio ( INR ) &lt; =1.5 ; 9 . Give sign informed consent enrollment . 1 . Function impairment vital organ ( heart , lung , kidney , etc ) , serious infection &gt; grade 2 adverse event ( Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 ) ; 2 . Histologically confirm positive resection margin ( R1 resection ) ; 3 . Previous current malignant tumor beyond HCC ; 4 . Allergy agent TACE regimen ; 5 . History organ transplantation ; 6 . Previously receive treatment HCC ; 7 . Pregnant breastfeed woman , woman childbearing potential without adequate contraception ; 8 . Neurological mental abnormality may affect cognitive assessment inform consent ; 9 . Concomitant antitumor therapy participate interventional clinical trial ; 10 . Other psychological , family social reason , would affect compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Chemoembolization</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Hepatocellular</keyword>
	<keyword>Microvessels invasion</keyword>
</DOC>